1. Tillisch J, Brunken R, Marshall R, Schwaiger M, Mandelkern M, Phelps M, et al. Reversibility of cardiac wall-motion abnormalities predicted by positron tomography.N Engl J Med 1986; 314: 884–888.
2. Haas F, Haehnel CJ, Picker W, Nekolla S, Martinoff S, Meisner H, et al. Preoperative positron emission tomographic viability assessment and perioperative and postoperative risk in patients with advanced ischemic heart disease.J Am Coll Cardiol 1997; 30: 1693–1700.
3. Landoni C, Lucignani G, Paolini G, Zuccari M, Galli L, Di Credico G, et al. Assessment of CABG-related risk in patients with CAD and LVD. Contribution of PET with [18F]FDG to the assessment of myocardial viability.J Cardiovasc Surg (Torino) 1999; 40: 363–372.
4. Yamagishi H, Shirai N, Takagi M, Yoshiyama M, Akioka K, Takeuchi K, et al. Identification of cardiac sarcoidosis with13N-NH3/18F-FDG PET.J Nucl Med 2003; 44 (7): 1030–1036.
5. Okumura W, Iwasaki T, Toyama T, Iso T, Arai M, Oriuchi N, et al. Usefulness of fasting18F-FDG PET in identification of cardiac sarcoidosis.J Nucl Med 2004; 45 (12): 1989–1998.